Chimerix’s (CMRX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a report released on Monday morning, MarketBeat.com reports. They currently have a $6.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on CMRX. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a report on Monday, November 11th. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Stock Performance

NASDAQ CMRX opened at $0.91 on Monday. The firm has a market capitalization of $82.18 million, a P/E ratio of -0.97 and a beta of 1.13. The stock has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $0.91. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30.

Hedge Funds Weigh In On Chimerix

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC grew its stake in shares of Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Chimerix in the second quarter valued at $137,000. Valeo Financial Advisors LLC boosted its holdings in Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares in the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.